Are Nanosonics Ltd shares in the buy zone?

I think it is fair to say that it hasn’t been a great 12 months for the Nanosonics Ltd. (ASX: NAN) share price.

During this time the infection control specialist’s shares have fallen a sizeable 20%.

The majority of this decline came following the release of its half-year results in February which were below expectations.

So with its shares down sharply over the 12 months, is this a buying opportunity?

The good.

Nanosonics has a huge opportunity in a market which its product is regarded as the best in its class. As of its half-year report, the company’s Trophon EPR ultrasound probe cleaning product had grown its global installed base to 16,000 units. This is just a fraction of the total addressable market that management estimates to be 120,000 units.

But soon it isn’t just going to be a one-trick pony. The company has two products in development targeting one or more new infection prevention solutions which it believes have unmet needs. Considering the strong reputation it has and its wide distribution network, I believe that these new products could be a big success and complement Trophon EPR’s growth.

The bad.

There’s no denying that its shares are a little on the expensive side at the moment. This was masked in FY 2017 by large one-offs but is now much more apparent. At present Nanosonics’ shares are priced at 118x trailing earnings or 11x sales. While I feel the company is capable of growing at a rate that justifies the premium, failure to do so could result in a sizeable share price decline.

Another concern I have is the rising level of short interest in its shares. Out of nowhere Nanosonics has suddenly become one of the most shorted shares on the local share market. The latest data out of ASIC reveals that 10.7% of its shares are being held short. As short sellers only tend to make a move when they have a high conviction of success, this build-up of short interest is worrying.

Should you invest?

I think Nanosonics is up there with Pro Medicus Limited (ASX: PME) and Volpara Health Technologies Ltd (ASX: VHT) as one of the best buy and hold options in the healthcare sector.

However, investors may want to keep a close eye on short interest levels. If short interest continues to build then it could weigh heavily on its share price performance in the short term.

Here are three top shares that could be even better options in the short term.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited and PRO Medicus Ltd. The Motley Fool Australia owns shares of VOLPARA FPO NZ. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…


The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!